VivoSeq
Other

Hypophosphatemia

11

Pipeline Programs↗

3

Active Trials↗

5

Companies Involved↗

Hypophosphatemia is an emerging landscape with 11 programs across 5 companies. The most active players are Bayer, New River Pharmaceuticals, Pierre Fabre Pharma GmbH. 5 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

80/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

1 program

Phase 1N

New River Pharmaceuticals

1 program

Phase 2P

Pierre Fabre Pharma GmbH

1 program

Phase 3Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

ApprovedM

Melinta Therapeutics, Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

10

clinical trials

Completed4 · 40%
Recruiting3 · 30%
Unknown status2 · 20%
Terminated1 · 10%

Clinical Trials

Trial Activity

10 trials

Effect of Hypophosphatemia on Neuro-excursion Efficiency During Mechanical Ventilator Weaning
Recruiting·PPeking Union Medical College·N/A·NCT06754670·70 enrolled
IV Iron-induced Hypophosphatemia After RYGB
Recruiting·—·Phase 4·NCT06350955·94 enrolled
Enteral Supplementation With Sodium Dihydrogen Phosphate and Disodium Hydrogen Phosphate Granules for the Treatment of Hypophosphatemia.
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·N/A·NCT07233889·60 enrolled
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
Completed·PPharmacosmos A/S·Phase 3·NCT03238911·123 enrolled
Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding
Completed·AAmerican Regent, Inc.·Phase 2·NCT01307007·69 enrolled
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
Completed·PPharmacosmos A/S·Phase 3·NCT03237065·122 enrolled
The Efficacy and Safety of Diluted Oral Phosphate Enema Versus Intravenous Sodium Glycerophosphate in The Treatment of Hypophosphatemia in ICU Patients
Completed·—·Phase 2/3·NCT06651892·42 enrolled
Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.
Terminated·Bayer logoBayer·Phase 1·NCT00622479·12 enrolled
Hypophosphatemia and Bronchiolitis
Unknown status·HHospices Civils de Lyon·N/A·NCT04814641·400 enrolled
Levels of 'Hypophosphatemia Affect Outcome of Septic Patients in ICU
Unknown status·—·Phase 4·NCT04519762·100 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)